Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company's diversified pipeline includes: 1) Mino-Lok®, an antibiotic lock solution for treating catheter-related bloodstream infections: enrolling patients in a Phase 3 Pivotal superiority trial; holds Fast Track designation by FDA. 2) LYMPHIR, a novel IL-2R immunotherapy with initial indication in CTCL: Citius is preparing to resubmit a Biologics License Application to FDA in early 2024; Citius has announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset; LYMPHIR holds orphan drug designation by FDA for the treatment of CTCL and PTCL. 3) Halo-Lido, a topical formulation for the relief of hemorrhoids: Phase 2b trial enrollment completed in March 2023.